Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

Clinico-pathological and epigenetic heterogeneity of diffuse gliomas with FGFR3::TACC3 fusion.

Tytuł:
Clinico-pathological and epigenetic heterogeneity of diffuse gliomas with FGFR3::TACC3 fusion.
Autorzy:
Métais A; GHU Psychiatrie et Neurosciences, Site Sainte-Anne, service de Neuropathologie, Paris, France.; Institut de Psychiatrie et Neurosciences de Paris (IPNP), UMR_S1266, INSERM, Equipe IMA-BRAIN (Imaging Biomarkers for Brain Development and Disorders), Université de Paris, Paris, France.
Tauziède-Espariat A; GHU Psychiatrie et Neurosciences, Site Sainte-Anne, service de Neuropathologie, Paris, France.; Institut de Psychiatrie et Neurosciences de Paris (IPNP), UMR_S1266, INSERM, Equipe IMA-BRAIN (Imaging Biomarkers for Brain Development and Disorders), Université de Paris, Paris, France.
Garcia J; APHM, CHU Timone, Service d'Anatomie Pathologique et de Neuropathologie, Marseille, France.
Appay R; APHM, CHU Timone, Service d'Anatomie Pathologique et de Neuropathologie, Marseille, France.; Aix-Marseille Univ, CNRS, INP, Inst Neurophysiopathol, Marseille, France.
Uro-Coste E; Department of Pathology, Toulouse University Hospital, Toulouse, France.
Meyronet D; Groupe Hospitalier Est, Département de Neuropathologie, Hospices Civils de Lyon, Bron, France.; Claude Bernard University Lyon 1, Lyon, France.; Department of Cancer cell plasticity - INSERM U1052, Cancer Research Center of Lyon, Lyon, France.
Maurage CA; Department of Pathology, Lille University Hospital, Lille, France.
Vandenbos F; Department of Neuropathology, Hôpital Pasteur, Nice, France.
Rigau V; Department of Pathology, Gui de Chauliac Hospital, Montpellier University Medical Center, Montpellier, France.
Chiforeanu DC; Service d'Anatomie et Cytologie Pathologiques, Pontchaillou University Hospital, Rennes, France.
Pallud J; Institut de Psychiatrie et Neurosciences de Paris (IPNP), UMR_S1266, INSERM, Equipe IMA-BRAIN (Imaging Biomarkers for Brain Development and Disorders), Université de Paris, Paris, France.; Department of Neurosurgery, GHU Paris Psychiatrie et Neurosciences, Paris, France.
Senova S; Departments of Neurosurgery and Psychiatry, Assistance Publique-Hôpitaux de Paris (APHP) Groupe Henri-Mondor Albert-Chenevier, Créteil, France.
Saffroy R; Department of Biochemistry and Oncogenetic, APHP, Paul-Brousse Hospital, Villejuif, France.
Colin C; Aix-Marseille Univ, CNRS, INP, Inst Neurophysiopathol, Marseille, France.
Edjlali M; Department of Radiology, APHP, Hôpitaux Raymond-Poincaré and Ambroise Paré, DMU Smart Imaging, U 1179 UVSQ/Paris-Saclay, GH Université Paris-Saclay, Paris, France.; Laboratoire d'imagerie Biomédicale Multimodale (BioMaps), CEA, CNRS, Inserm, Service Hospitalier Frédéric Joliot, Université Paris-Saclay, Orsay, France.
Varlet P; GHU Psychiatrie et Neurosciences, Site Sainte-Anne, service de Neuropathologie, Paris, France.; Institut de Psychiatrie et Neurosciences de Paris (IPNP), UMR_S1266, INSERM, Equipe IMA-BRAIN (Imaging Biomarkers for Brain Development and Disorders), Université de Paris, Paris, France.
Figarella-Branger D; APHM, CHU Timone, Service d'Anatomie Pathologique et de Neuropathologie, Marseille, France. .; Aix-Marseille Univ, CNRS, INP, Inst Neurophysiopathol, Marseille, France. .
Corporate Authors:
Biopathology RENOCLIP-LOC network
Źródło:
Acta neuropathologica communications [Acta Neuropathol Commun] 2023 Jan 16; Vol. 11 (1), pp. 14. Date of Electronic Publication: 2023 Jan 16.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
Język:
English
Imprint Name(s):
Original Publication: London : BioMed Central, [2013]-
MeSH Terms:
Glioblastoma*/genetics
Glioma*/genetics
Glioma*/pathology
Brain Neoplasms*/genetics
Brain Neoplasms*/pathology
Ganglioglioma*/genetics
Adult ; Humans ; Child ; Mutation/genetics ; Prognosis ; Epigenesis, Genetic ; DNA ; Isocitrate Dehydrogenase/genetics ; Receptor, Fibroblast Growth Factor, Type 3/genetics ; Microtubule-Associated Proteins/genetics
References:
Science. 2012 Sep 7;337(6099):1231-5. (PMID: 22837387)
Neuropathology. 2018 Oct;38(5):557-560. (PMID: 30051533)
Bioorg Med Chem Lett. 2022 Mar 15;60:128584. (PMID: 35085722)
J Neuropathol Exp Neurol. 2021 Sep 27;80(11):1052–1059. (PMID: 34580728)
Oncologist. 2017 Dec;22(12):1478-1490. (PMID: 28912153)
Nature. 2018 Mar 22;555(7697):469-474. (PMID: 29539639)
Neurooncol Pract. 2020 Nov 20;8(2):209-221. (PMID: 33898054)
Front Oncol. 2020 Nov 12;10:579762. (PMID: 33282733)
Neuropathol Appl Neurobiol. 2022 Feb;48(2):e12769. (PMID: 34551121)
Acta Neuropathol. 2017 Mar;133(3):417-429. (PMID: 27812792)
CNS Oncol. 2019 Jun;8(2):CNS37. (PMID: 31290679)
Neuropathol Appl Neurobiol. 2022 Oct;48(6):e12834. (PMID: 35836307)
Acta Neuropathol Commun. 2020 Nov 9;8(1):186. (PMID: 33168106)
Acta Neuropathol. 2016 Jun;131(6):833-45. (PMID: 26810070)
Neuropathol Appl Neurobiol. 2021 Apr;47(3):406-414. (PMID: 33336421)
Acta Neuropathol. 2018 Aug;136(2):181-210. (PMID: 29967940)
BMC Neurol. 2020 Apr 6;20(1):123. (PMID: 32252664)
Neuro Oncol. 2022 Oct 3;24(10):1749-1762. (PMID: 35395677)
Clin Cancer Res. 2015 Jul 15;21(14):3307-17. (PMID: 25609060)
Brain Pathol. 2022 Jul;32(4):e13060. (PMID: 35218102)
Acta Neuropathol Commun. 2019 Apr 29;7(1):63. (PMID: 31036092)
JCO Precis Oncol. 2021 May 20;5:. (PMID: 34250399)
Acta Neuropathol. 2021 Jan;141(1):123-125. (PMID: 33226472)
NPJ Precis Oncol. 2017 Sep 7;1(1):29. (PMID: 29872711)
Surg Neurol Int. 2021 Sep 20;12:470. (PMID: 34621585)
Brain Pathol. 2021 Jul;31(4):e12929. (PMID: 33336392)
Neuropathol Appl Neurobiol. 2022 Aug;48(5):e12813. (PMID: 35293634)
Brain Pathol. 2018 Sep;28(5):674-683. (PMID: 28976058)
Acta Neuropathol. 2022 Jul;144(1):155-157. (PMID: 35567606)
Clin Cancer Res. 2022 Jun 1;28(11):2270-2277. (PMID: 35344029)
Lancet Oncol. 2009 May;10(5):459-66. (PMID: 19269895)
Neuro Oncol. 2017 Sep 01;19(9):1206-1216. (PMID: 28379477)
Oncologist. 2021 Mar;26(3):173-177. (PMID: 32949176)
Neuro Oncol. 2020 Nov 26;22(11):1614-1624. (PMID: 32413119)
Neuro Oncol. 2021 Aug 2;23(8):1231-1251. (PMID: 34185076)
J Neuropathol Exp Neurol. 2018 Jun 1;77(6):437-442. (PMID: 29718398)
Contributed Indexing:
Investigator: A Rousseau; C Godfraind; G Gauchotte; K Mokhtari; F Bielle; F Escande; F Fina
Keywords: 2021 WHO classification of CNS tumours; DNA-methylation profiling; FGFR3:TACC3 fusion; Glioblastoma; Pediatric low grade glioma
Substance Nomenclature:
9007-49-2 (DNA)
EC 1.1.1.41 (Isocitrate Dehydrogenase)
EC 2.7.10.1 (FGFR3 protein, human)
EC 2.7.10.1 (Receptor, Fibroblast Growth Factor, Type 3)
0 (TACC3 protein, human)
0 (Microtubule-Associated Proteins)
Entry Date(s):
Date Created: 20230116 Date Completed: 20230118 Latest Revision: 20230202
Update Code:
20240105
PubMed Central ID:
PMC9843943
DOI:
10.1186/s40478-023-01506-z
PMID:
36647073
Czasopismo naukowe
Background: Gliomas with FGFR3::TACC3 fusion mainly occur in adults, display pathological features of glioblastomas (GB) and are usually classified as glioblastoma, IDH-wildtype. However, cases demonstrating pathological features of low-grade glioma (LGG) lead to difficulties in classification and clinical management. We report a series of 8 GB and 14 LGG with FGFR3:TACC3 fusion in order to better characterize them.
Methods: Centralized pathological examination, search for TERT promoter mutation and DNA-methylation profiling were performed in all cases. Search for prognostic factors was done by the Kaplan-Meir method.
Results: TERT promoter mutation was recorded in all GB and 6/14 LGG. Among the 7 cases with a methylation score > 0.9 in the classifier (v12.5), 2 were classified as glioblastoma, 4 as ganglioglioma (GG) and 1 as dysembryoplastic neuroepithelial tumor (DNET). t-SNE analysis showed that the 22 cases clustered into three groups: one included 12 cases close to glioblastoma, IDH-wildtype methylation class (MC), 5 cases each clustered with GG or DNET MC but none with PLNTY MC. Unsupervised clustering analysis revealed four groups, two of them being clearly distinct: 5 cases shared age (< 40), pathological features of LGG, lack of TERT promoter mutation, FGFR3(Exon 17)::TACC3(Exon 10) fusion type and LGG MC. In contrast, 4 cases shared age (> 40), pathological features of glioblastoma, and were TERT-mutated. Relevant factors associated with a better prognosis were age < 40 and lack of TERT promoter mutation.
Conclusion: Among gliomas with FGFR3::TACC3 fusion, age, TERT promoter mutation, pathological features, DNA-methylation profiling and fusion subtype are of interest to determine patients' risk.
(© 2023. The Author(s).)
Zaloguj się, aby uzyskać dostęp do pełnego tekstu.

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies